{"filings":[{"id":2034316,"accession_number":"0000200406-26-000167","cik":200406,"company_name":"JOHNSON & JOHNSON","ticker":"JNJ","form_type":"8-K","filed_at":"2026-08-04T12:48:52+00:00","items":["5.02","9.01"],"status":"ready","headline":"Jennifer Taubert, EVP and Worldwide Chairman of Innovative Medicine, to retire Sept 1, 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jennifer Taubert retiring as EVP, Worldwide Chairman of Innovative Medicine and member of Executive Committee.","Retirement effective September 1, 2026.","No successor has been named at this time.","Announcement made on August 4, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":556765211700.5051,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1943199,"accession_number":"0000200406-26-000163","cik":200406,"company_name":"JOHNSON & JOHNSON","ticker":"JNJ","form_type":"8-K","filed_at":"2026-07-29T21:25:05+00:00","items":["7.01","9.01"],"status":"ready","headline":"JNJ completes Firefly acquisition, enters Sail collaboration; cuts 2026 EPS guidance by $0.64","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["2026 adjusted operational EPS midpoint lowered to $10.94 from $11.58; adjusted EPS midpoint to $11.04 from $11.68.","Firefly acquisition reduces 2026 EPS by ~$0.46; Sail collaboration reduces by ~$0.18.","2027 adjusted EPS expected to decrease by ~$1.36 ($0.08 Firefly, $1.28 Sail assuming milestones).","Operational sales guidance maintained at $100.3B-$100.9B; adjusted pre-tax operating margin guidance cut by ~150 bps.","Transactions include completion of Firefly Bio acquisition and strategic agreements with Sail Biomedicines."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":556765211700.5051,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1894797,"accession_number":"0000200406-26-000155","cik":200406,"company_name":"JOHNSON & JOHNSON","ticker":"JNJ","form_type":"8-K","filed_at":"2026-07-28T00:15:31+00:00","items":["7.01","9.01"],"status":"ready","headline":"Johnson & Johnson agrees to $5.5B comprehensive resolution of ovarian talc litigation","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Agreement with plaintiff firms leading federal MDL and state court proceedings, conditioned on at least 95% participation of remaining claims.","$5.5 billion total commitment; first payment of up to $3 billion in 2027, no further payments before 2028.","Per claim payment structure under the comprehensive resolution.","Resolution covers ovarian talc litigation, a major ongoing legal matter for JNJ."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":556765211700.5051,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1646676,"accession_number":"0000200406-26-000146","cik":200406,"company_name":"JOHNSON & JOHNSON","ticker":"JNJ","form_type":"8-K","filed_at":"2026-07-15T11:49:04+00:00","items":["2.02","9.01"],"status":"ready","headline":"JNJ Q2 2026 revenue up 6.6% to $25.3B; adjusted EPS $2.90 (+4.7%)","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 sales $25,310M (+6.6% operational, +1.0% currency); GAAP net earnings $5,534M (-0.1%).","GAAP diluted EPS $2.27 (-0.9%); adjusted diluted EPS $2.90 (+4.7%).","Innovative Medicine sales $16,384M (+7.8%); MedTech $8,926M (+4.5%).","US sales $14,533M (+7.3%); International $10,777M (+5.7%)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":556765211700.5051,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":97153,"accession_number":"0000200406-26-000089","cik":200406,"company_name":"JOHNSON & JOHNSON","ticker":"JNJ","form_type":"8-K","filed_at":"2026-04-28T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"JNJ shareholders elect all 12 directors, approve say-on-pay, reject independent chair proposal","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All 12 director nominees elected with strong support (over 1.65B shares for each).","Advisory say-on-pay approved with ~94.5% of votes cast in favor (1.64B for, 91.8M against).","Ratification of PwC as auditor for 2026 passed with ~93% of votes cast (1.91B for, 138.6M against).","Shareholder proposal for independent board chair defeated with ~76.6% against (1.33B against vs 406M for)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":556765211700.5051,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":97152,"accession_number":"0000200406-26-000076","cik":200406,"company_name":"JOHNSON & JOHNSON","ticker":"JNJ","form_type":"8-K","filed_at":"2026-04-14T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"JNJ Q1 adj. EPS $2.70 (down 1.4% YoY); raises dividend 3.1% to $1.34/qtr","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 revenue $24.06B, up 9.9% YoY (operational growth 6.4%, currency 3.5%).","GAAP net earnings $5.24B ($2.14 diluted EPS) vs $11.0B ($4.54) in Q1 2025, down 52% due to prior-year other income.","Adjusted net earnings $6.61B ($2.70 diluted EPS) vs $6.71B ($2.77), down 1.4% YoY.","Dividend increased 3.1% to $1.34 per quarter ($5.36 annual), marking 64th consecutive annual increase; payable June 9, 2026 to record May 26.","Innovative Medicine segment sales $15.4B (+11.2%); MedTech $8.6B (+7.7%)."],"consensus_eps_estimate":null,"consensus_eps_actual":2.14,"consensus_revenue_estimate":null,"consensus_revenue_actual":24062000000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":556765211700.5051,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":111698,"accession_number":"0000200406-26-000002","cik":200406,"company_name":"JOHNSON & JOHNSON","ticker":"JNJ","form_type":"8-K","filed_at":"2026-01-21T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"JNJ Q4 2025 sales $24.6B (+9.1% YoY), net earnings $5.1B ($2.10 EPS); adj. EPS $2.46","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 sales $24,564M (+9.1% YoY); full-year sales $94,193M (+6.0% YoY).","Q4 net earnings $5,116M ($2.10 diluted EPS) vs $3,431M ($1.41) a year ago.","Adjusted Q4 net earnings $6,009M ($2.46 adj. diluted EPS) vs $4,946M ($2.04).","R&D expense decreased 19.7% YoY to $4,252M; effective tax rate was -3.0%.","MedTech segment sales $8,801M (+7.5% YoY); Innovative Medicine $15,763M (+10.0% YoY)."],"consensus_eps_estimate":null,"consensus_eps_actual":11.03,"consensus_revenue_estimate":null,"consensus_revenue_actual":94193000000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":556765211700.5051,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":128330,"accession_number":"0000200406-25-000201","cik":200406,"company_name":"JOHNSON & JOHNSON","ticker":"JNJ","form_type":"8-K","filed_at":"2025-10-14T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"JNJ reports Q3 adjusted EPS $2.80; plans to spin off Orthopaedics as DePuy Synthes","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Q3 revenue $23,993M (+6.8% YoY); GAAP EPS $2.12, adjusted EPS $2.80 (+15.7% YoY).","Innovative Medicine sales $15,563M (+6.8% operational); MedTech sales $8,430M (+6.8% operational).","Intends to separate Orthopaedics business into standalone DePuy Synthes; FY2024 ortho sales ~$9.2B.","Target completion in 18-24 months; Namal Nawana appointed Worldwide President of DePuy Synthes.","Separation aims to shift MedTech portfolio to higher-growth/margin markets; JNJ retains focus on six growth areas."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":556765211700.5051,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":145135,"accession_number":"0000200406-25-000190","cik":200406,"company_name":"JOHNSON & JOHNSON","ticker":"JNJ","form_type":"8-K","filed_at":"2025-09-09T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Johnson & Johnson elects John Morikis to Board of Directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["John Morikis elected to JNJ Board effective Sept. 8, 2025; will serve on Audit and Compensation Committees.","Morikis was Executive Chairman, President & CEO of Sherwin-Williams from 2016 to 2024.","He joined Sherwin-Williams in 1984 and served as President & COO from 2006-2016.","As non-employee director, he will receive standard director compensation per 2025 Proxy Statement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":556765211700.5051,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":145134,"accession_number":"0000200406-25-000170","cik":200406,"company_name":"JOHNSON & JOHNSON","ticker":"JNJ","form_type":"8-K","filed_at":"2025-07-16T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"JNJ Q2 sales $23.7B (+5.8%); GAAP EPS $2.29 (+18.7%); adj. EPS $2.77 (-1.8%)","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 sales $23,743M (+5.8% YoY); U.S. $13,544M (+7.8%), International $10,199M (+3.2%).","GAAP net earnings $5,537M; diluted EPS $2.29 vs $1.93 a year ago (+18.7%).","Adjusted net earnings $6,699M; adjusted diluted EPS $2.77 vs $2.82 (-1.8%).","Innovative Medicine sales $15,202M (+4.9%); MedTech sales $8,541M (+7.3%).","Gross margin 67.9% vs 69.4% year ago; R&D expense $3,516M (14.8% of sales)."],"consensus_eps_estimate":null,"consensus_eps_actual":6.82,"consensus_revenue_estimate":null,"consensus_revenue_actual":45636000000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":556765211700.5051,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":163525,"accession_number":"0000200406-25-000152","cik":200406,"company_name":"JOHNSON & JOHNSON","ticker":"JNJ","form_type":"8-K","filed_at":"2025-06-10T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Daniel Pinto elected to JNJ Board effective July 1, 2025; to serve on Audit & Compensation Committees","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Election of Daniel Pinto, President of JPMorganChase, to J&J Board effective July 1, 2025.","Pinto will serve on Audit Committee and Compensation & Benefits Committee.","He will become Vice Chairman of JPMorganChase from July 1, 2025 until retirement end of 2026.","J&J paid JPMorganChase approx. $39.2M in FY2024 for banking services including M&A advisory.","Pinto will receive standard non-employee director compensation per 2025 Proxy Statement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":556765211700.5051,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":163524,"accession_number":"0000200406-25-000141","cik":200406,"company_name":"JOHNSON & JOHNSON","ticker":"JNJ","form_type":"8-K","filed_at":"2025-04-30T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Director D. Adamczyk to retire from JNJ board May 31; shareholders re-elect all 11 nominees and approve Say on Pay","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Director D. Adamczyk retiring effective May 31, 2025 to join Goldman Sachs as Partner; no disagreement with management.","All 11 director nominees elected at Annual Meeting on April 24; say-on-pay approved (1.56B for, 142M against).","Shareholders ratified PwC as auditor for 2025 (1.89B for, 141M against).","Two shareholder proposals defeated: golden parachutes vote (92.6M for, 1.61B against) and human rights assessment (188M for, 1.50B against)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":556765211700.5051,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":163523,"accession_number":"0000200406-25-000110","cik":200406,"company_name":"JOHNSON & JOHNSON","ticker":"JNJ","form_type":"8-K","filed_at":"2025-04-15T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"JNJ Q1 adj EPS $2.77 (+2.2%), revenue $21.9B; dividend +4.8% to $1.30","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP net earnings $11.0B ($4.54 diluted EPS) vs $3.3B ($1.34), boosted by $7.3B other income.","Adjusted net earnings $6.71B ($2.77 diluted EPS) vs $6.58B ($2.71), up 1.9% operationally.","Worldwide sales $21.89B, up 2.4% reported, 4.2% operational; US +5.9%, International -1.8%.","Innovative Medicine $13.87B (+2.3% reported, +4.2% op); MedTech $8.02B (+2.5% reported, +4.1% op).","Dividend raised 4.8% to $1.30/quarter, payable June 10, 2025; record May 27, 2025; 63rd annual increase."],"consensus_eps_estimate":null,"consensus_eps_actual":4.54,"consensus_revenue_estimate":null,"consensus_revenue_actual":21893000000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":556765211700.5051,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":163522,"accession_number":"0000200406-25-000106","cik":200406,"company_name":"JOHNSON & JOHNSON","ticker":"JNJ","form_type":"8-K","filed_at":"2025-04-03T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Bankruptcy court denies J&J's Red River Talc prepackaged plan; $7B reserve reversed","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["U.S. Bankruptcy Court for Southern District of Texas denied confirmation of Red River Talc LLC's prepackaged plan on March 31, 2025.","Johnson & Johnson will reverse approximately $7 billion from amounts previously reserved for the bankruptcy resolution.","The decision is a setback in J&J's strategy to resolve talc-related lawsuits through subsidiary bankruptcy.","Press release attached as Exhibit 99.1 details the announcement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":556765211700.5051,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":181439,"accession_number":"0001193125-25-036773","cik":200406,"company_name":"JOHNSON & JOHNSON","ticker":"JNJ","form_type":"8-K","filed_at":"2025-02-26T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Johnson & Johnson completes €4B multi-tranche euro note offering","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued €600M 2.700% Notes due 2029, €700M 3.050% Notes due 2033, and €1B 3.350% Notes due 2037.","Also issued €700M 3.600% Notes due 2045 and €1B 3.700% Notes due 2055.","Total aggregate principal amount of €4 billion across five tranches.","Underwriting agreement with Citigroup, Deutsche Bank, Goldman Sachs and others dated Feb 19, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":556765211700.5051,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":181438,"accession_number":"0001193125-25-030851","cik":200406,"company_name":"JOHNSON & JOHNSON","ticker":"JNJ","form_type":"8-K","filed_at":"2025-02-20T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Johnson & Johnson completes $5B debt offering across five tranches with coupons from 4.500% to 5.000%","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $750M 4.500% notes due 2027, $750M 4.550% notes due 2028, and $1B 4.700% notes due 2030.","Issued $1.25B 4.850% notes due 2032 and $1.25B 5.000% notes due 2035.","Underwriting agreement signed Feb 18 with Citigroup, BofA Securities, and J.P. Morgan as representatives.","Notes sold under existing S-3 shelf registration; closing occurred Feb 20, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":556765211700.5051,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":181437,"accession_number":"0000200406-25-000003","cik":200406,"company_name":"JOHNSON & JOHNSON","ticker":"JNJ","form_type":"8-K","filed_at":"2025-01-22T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"JNJ Q4 net earnings down 17%, revenue up 5.3% to $22.52B; adjusted EPS $2.04","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 sales $22.52B, +5.3% YoY; net earnings $3.43B, -17% from $4.13B; diluted EPS $1.41.","Adjusted net earnings $4.95B, adjusted EPS $2.04, down 10.9% from $2.29.","Innovative Medicine (ex-COVID) sales $14.33B (+4.8%); MedTech sales $8.19B (+6.7%).","R&D expense rose 18.3% to $5.30B; operating margin contracted to 17.3% from 22.6%.","Full-year sales $88.82B, +4.3% vs $85.16B; ex-COVID sales +5.5%."],"consensus_eps_estimate":null,"consensus_eps_actual":5.79,"consensus_revenue_estimate":null,"consensus_revenue_actual":88821000000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":556765211700.5051,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":181436,"accession_number":"0000200406-25-000007","cik":200406,"company_name":"JOHNSON & JOHNSON","ticker":"JNJ","form_type":"8-K/A","filed_at":"2025-01-22T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"Johnson & Johnson files 8-K/A to fix press release format; no impact on numbers","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Amendment aligns format of Reported Sales line in Exhibit 99.1 with newswire press release.","No reported Q4 or Full Year 2024 sales numbers are changed by this update.","Original press release covering period ended December 29, 2024 was issued January 22, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.0,"calibrated_materiality_score":0.0,"market_cap_usd":556765211700.5051,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":198243,"accession_number":"0000200406-24-000088","cik":200406,"company_name":"JOHNSON & JOHNSON","ticker":"JNJ","form_type":"8-K","filed_at":"2024-10-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Johnson & Johnson Q3 sales up 5.2% to $22.5B; GAAP EPS down 34% to $1.11 on higher R&D and other charges","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Worldwide sales $22.47B (+5.2% reported, +6.3% operational); MedTech up 5.8%, Innovative Medicine up 4.9%.","GAAP net earnings from continuing ops $2.69B ($1.11 diluted EPS), down 37.5% YoY; adjusted net earnings $5.88B ($2.42 adjusted EPS), down 13.3%.","R&D expense jumped 43.7% to $4.95B (22.0% of sales); other expense net $1.80B vs $0.50B in prior year.","GAAP effective tax rate 19.3% vs 17.4%; adjusted tax rate 19.3% vs 15.6%.","Discontinued ops had no contribution vs $21.7B in prior year (related to Kenvue separation)."],"consensus_eps_estimate":null,"consensus_eps_actual":4.38,"consensus_revenue_estimate":null,"consensus_revenue_actual":66301000000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":556765211700.5051,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":214359,"accession_number":"0000200406-24-000083","cik":200406,"company_name":"JOHNSON & JOHNSON","ticker":"JNJ","form_type":"8-K","filed_at":"2024-09-20T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"J&J subsidiary Red River Talc files Chapter 11 for cosmetic talc settlement, increasing contribution by $1.75B to ~$8B","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Red River Talc LLC filed voluntary prepackaged Chapter 11 in Southern District of Texas.","Approximately 83% of current ovarian cancer claimants support the proposed bankruptcy plan.","Settlement contribution increased by $1.75 billion to a present value of approximately $8 billion.","Aims to resolve all current and future U.S. cosmetic talc claims against Johnson & Johnson."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":556765211700.5051,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":214358,"accession_number":"0000200406-24-000081","cik":200406,"company_name":"JOHNSON & JOHNSON","ticker":"JNJ","form_type":"8-K","filed_at":"2024-09-10T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Director D.S. Davis retires from Johnson & Johnson board effective Sept 10, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["D.S. Davis retired as Director after transitioning Audit Committee Chair duties to D. Adamczyk.","Retirement is for personal reasons, not due to any disagreement with management or operations.","Audit Committee Chair responsibilities successfully transitioned to D. Adamczyk prior to departure."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":556765211700.5051,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":214357,"accession_number":"0000200406-24-000079","cik":200406,"company_name":"JOHNSON & JOHNSON","ticker":"JNJ","form_type":"8-K","filed_at":"2024-08-26T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Johnson & Johnson CHRO Peter Fasolo to retire effective Oct 1, 2024","summary_kind":"llm","event_type":"leadership","confidence":"medium","bullets":["Peter M. Fasolo, EVP and CHRO, will step down from role and Executive Committee on October 1, 2024.","Fasolo will depart the company at the end of 2024; no successor announced in the filing.","Retirement is described as elected, with no mention of dispute or performance issues."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":556765211700.5051,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":214356,"accession_number":"0000200406-24-000071","cik":200406,"company_name":"JOHNSON & JOHNSON","ticker":"JNJ","form_type":"8-K","filed_at":"2024-07-17T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"J&J Q2 revenue up 4.3% but GAAP EPS falls 5.9%; adjusted EPS rises 10.2%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 2024 revenue $22.4B, +4.3% YoY; GAAP diluted EPS $1.93, -5.9% YoY; adjusted diluted EPS $2.82, +10.2% YoY.","Innovative Medicine (ex-COVID) revenue $14.3B, +6.5% operational; MedTech revenue $7.96B, +2.2% reported.","GAAP net earnings from continuing ops $4.69B, -12.8% YoY, impacted by $194M IPR&D impairments and prior-year gains.","Adjusted net earnings from continuing ops $6.84B, +1.6% YoY; effective tax rate up to 18.5% from 14.7%.","Share repurchase reduced diluted share count to 2,422M from 2,626M YoY, boosting adjusted EPS growth."],"consensus_eps_estimate":null,"consensus_eps_actual":3.27,"consensus_revenue_estimate":null,"consensus_revenue_actual":43830000000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":556765211700.5051,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":233578,"accession_number":"0001193125-24-142828","cik":200406,"company_name":"JOHNSON & JOHNSON","ticker":"JNJ","form_type":"8-K","filed_at":"2024-05-20T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Johnson & Johnson completes $4.0B USD and €2.5B multi-tranche note offering","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $1.15B 4.800% notes due 2029, $1.15B 4.900% notes due 2031, $850M 4.950% notes due 2034, $850M 5.250% notes due 2054.","Issued €700M 3.200% notes due 2032, €800M 3.350% notes due 2036, €1.0B 3.550% notes due 2044.","Offerings completed on May 20, 2024 under existing shelf registration; underwriting agreements with J.P. Morgan, BofA, Citi, and others.","Proceeds intended for general corporate purposes (not explicitly stated in filing but typical for such issuances)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":556765211700.5051,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":233577,"accession_number":"0000200406-24-000053","cik":200406,"company_name":"JOHNSON & JOHNSON","ticker":"JNJ","form_type":"8-K","filed_at":"2024-05-17T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Johnson & Johnson fully divests remaining Kenvue stake via debt-for-equity exchange","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["On May 17, 2024, JNJ exchanged its remaining 182.3M Kenvue shares for $3.6B commercial paper, eliminating its Kenvue ownership.","JNJ issued $3.6B commercial paper on May 15, 2024 for general corporate purposes, then used it to complete the exchange.","This completes the separation of Consumer Health business announced in Nov 2021; JNJ no longer holds any Kenvue shares.","The commercial paper was satisfied and discharged upon completion of the exchange."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":556765211700.5051,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":233576,"accession_number":"0000200406-24-000048","cik":200406,"company_name":"JOHNSON & JOHNSON","ticker":"JNJ","form_type":"8-K","filed_at":"2024-05-01T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"JNJ proposes $6.475B talc settlement plan; Q1 GAAP EPS cut to $1.34","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Proposed plan pays $6.475B present value ($8.4B nominal over 25 years) to resolve all ovarian cancer cosmetic talc claims.","Incremental $2.7B charge; total talc reserve now ~$11B present value ($13.7B nominal) as of Q1 2024.","Previously reported GAAP net earnings reduced from $5.4B to $3.3B; EPS from $2.20 to $1.34 for Q1 2024.","Q1 2024 adjusted EPS of $2.71 unchanged; sales $21.38B (+2.3% YoY).","No impact to mesothelioma, state consumer claims; plan excludes those categories."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":556765211700.5051,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":233575,"accession_number":"0000200406-24-000043","cik":200406,"company_name":"JOHNSON & JOHNSON","ticker":"JNJ","form_type":"8-K","filed_at":"2024-04-29T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"Johnson & Johnson adopts amended bylaws and holds 2024 annual meeting; all directors elected","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amended by-laws effective April 25, 2024 updated special meeting rules, universal proxy compliance, proxy access, and indemnification.","Annual meeting elected all 13 director nominees; say-on-pay passed with ~89% of votes cast.","PwC ratified as independent auditor for FY2024 with ~94% approval.","Shareholder proposal on gender-based compensation gaps did not pass; 97% of votes cast against.","Bylaws now specify CEO also serves as President unless Board designates otherwise."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":556765211700.5051,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":233574,"accession_number":"0000200406-24-000031","cik":200406,"company_name":"JOHNSON & JOHNSON","ticker":"JNJ","form_type":"8-K","filed_at":"2024-04-16T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"JNJ reports Q1 adjusted EPS $2.71 (+12.4% YoY); declares 4.2% dividend increase to $1.24/quarter","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Worldwide sales $21.38B, up 2.3% total (6.0% ex-COVID-19 vaccine); MedTech up 4.5%, Innovative Medicine ex-vaccine up 6.9%","GAAP net earnings from continuing ops $5.35B ($2.20 diluted EPS) vs $0.49B loss in prior year (large litigation charges skewed comparison)","Adjusted net earnings $6.58B, up 3.8%; adjusted diluted EPS $2.71 vs $2.41, +12.4%","Board raises quarterly dividend to $1.24/share (from $1.19), a 4.2% increase; marks 62nd consecutive annual increase","New indicated annual dividend $4.96/share; payable June 4, 2024 to holders of record May 21, 2024"],"consensus_eps_estimate":null,"consensus_eps_actual":1.34,"consensus_revenue_estimate":null,"consensus_revenue_actual":21383000000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":556765211700.5051,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":233573,"accession_number":"0000200406-24-000036","cik":200406,"company_name":"JOHNSON & JOHNSON","ticker":"JNJ","form_type":"8-K/A","filed_at":"2024-04-16T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"Johnson & Johnson corrects FY2024 operational sales guidance midpoint to $88.9B","summary_kind":"llm","event_type":"earnings","confidence":"medium","bullets":["Full-year 2024 operational sales guidance midpoint revised to $88.9B from $88.0B due to typo correction.","Amendment No. 1 to Form 8-K filed April 16, 2024 corrects error in prior press release; no other changes.","Press release for Q1 2024 (period ended March 31, 2024) otherwise unchanged; specifics not provided here."],"consensus_eps_estimate":null,"consensus_eps_actual":1.34,"consensus_revenue_estimate":null,"consensus_revenue_actual":21383000000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":556765211700.5051,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":251641,"accession_number":"0000200406-24-000004","cik":200406,"company_name":"JOHNSON & JOHNSON","ticker":"JNJ","form_type":"8-K","filed_at":"2024-01-23T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"JNJ Q4 2023 revenue $21.4B (+7.3% YoY), adjusted EPS $2.29 (+11.7%)","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 sales $21,395M (+7.3% YoY); FY 2023 sales $85,159M (+6.5% YoY).","Q4 net earnings from continuing ops $4,132M (diluted EPS $1.70, +39.3% YoY).","Adjusted Q4 net earnings from continuing ops $5,562M (diluted EPS $2.29, +11.7% YoY).","Innovative Medicine ex-COVID vaccine grew 9.7% in Q4; MedTech grew 13.3%.","FY 2023 operational sales growth 7.4% total, 8.0% ex-COVID vaccine."],"consensus_eps_estimate":null,"consensus_eps_actual":13.72,"consensus_revenue_estimate":null,"consensus_revenue_actual":85159000000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":556765211700.5051,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":269239,"accession_number":"0000200406-23-000115","cik":200406,"company_name":"JOHNSON & JOHNSON","ticker":"JNJ","form_type":"8-K","filed_at":"2023-12-05T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Eugene A. Woods elected to Johnson & Johnson Board of Directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Eugene A. Woods, CEO of Advocate Health, joined the board as a non-employee director effective Nov 30, 2023.","Mr. Woods will receive standard non-employee director compensation as described in 2023 Proxy Statement.","Advocate Health purchased ~$175M of Johnson & Johnson products in FY2022; JNJ paid <$1M for clinical trials."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":556765211700.5051,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":269238,"accession_number":"0000200406-23-000112","cik":200406,"company_name":"JOHNSON & JOHNSON","ticker":"JNJ","form_type":"8-K","filed_at":"2023-12-05T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"JNJ holds investor meeting at NYSE to present strategy, pipeline, and long-term outlook","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["December 5, 2023: JNJ host Enterprise Business Review at NYSE for the investment community.","Presented overarching strategy, Innovative Medicine and MedTech pipelines, and long-term financial outlook.","Press release and webcast materials available at https://jnjbusinessreview.q4ir.com/.","No specific financial guidance, numbers, or changes disclosed in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":556765211700.5051,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":269237,"accession_number":"0000200406-23-000109","cik":200406,"company_name":"JOHNSON & JOHNSON","ticker":"JNJ","form_type":"8-K","filed_at":"2023-11-30T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"JNJ completes Laminar acquisition for $400M upfront; cuts FY2023 adjusted EPS guidance by $0.17","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Upfront payment of $400M (subject to adjustments) plus potential clinical/regulatory milestone payments.","Laminar's LAAX device uses rotational motion to eliminate left atrial appendage; FDA approved U.S. pivotal study starting in early 2024.","FY2023 adjusted operational EPS guidance revised to $9.85-$9.91; reported to $9.90-$9.96, reflecting $0.17 IPR&D charge.","Acquisition expected to reduce FY2024 EPS by approximately $0.15.","Biosense Webster (JNJ MedTech) will integrate Laminar; targets ~38M AFib patients worldwide."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":556765211700.5051,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":269236,"accession_number":"0000200406-23-000105","cik":200406,"company_name":"JOHNSON & JOHNSON","ticker":"JNJ","form_type":"8-K","filed_at":"2023-11-27T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Johnson & Johnson adopts new deferred compensation plan for management","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Plan adopted Nov. 21, 2023; allows deferral of up to 50% of base salary and 100% of annual cash bonus.","Participants fully vested at all times; no matching or discretionary company contributions.","Payments made upon separation from service or at an in-service date elected by the participant.","Executive Income Deferral Plan (EIDP) closed to new deferrals; existing balances may transfer options.","Plan is unfunded, nonqualified, and limited to pay grade 50+ highly-compensated employees."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":556765211700.5051,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":269235,"accession_number":"0000200406-23-000096","cik":200406,"company_name":"JOHNSON & JOHNSON","ticker":"JNJ","form_type":"8-K","filed_at":"2023-10-23T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Johnson & Johnson EVP MedTech Ashley McEvoy resigns effective October 20, 2023","summary_kind":"llm","event_type":"leadership","confidence":"medium","bullets":["McEvoy resigned as Executive Vice President, Worldwide Chair MedTech and Executive Committee member.","Resignation effective October 20, 2023; she will remain through Q1 2024 for transition.","No replacement or reason for resignation was disclosed in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":556765211700.5051,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":269234,"accession_number":"0000200406-23-000094","cik":200406,"company_name":"JOHNSON & JOHNSON","ticker":"JNJ","form_type":"8-K","filed_at":"2023-10-17T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"JNJ Q3 adjusted EPS $2.66 rises 19% YoY; $21.7B gain from Kenvue separation","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 sales $21.35B (+6.8% YoY); adjusted diluted EPS $2.66 (+19.3% YoY from $2.23).","Innovative Medicine revenue $13.89B (+5.1% reported); MedTech $7.46B (+10.0%).","U.S. sales grew 11.1% to $11.996B; international sales rose 1.6% to $9.355B.","Discontinued ops net earnings $21.7B (incl. gain from Kenvue separation) vs $148M prior year.","Adjusted pretax income from continuing ops $8.03B, up 13.8% YoY."],"consensus_eps_estimate":null,"consensus_eps_actual":11.95,"consensus_revenue_estimate":null,"consensus_revenue_actual":63764000000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":556765211700.5051,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":286228,"accession_number":"0000200406-23-000091","cik":200406,"company_name":"JOHNSON & JOHNSON","ticker":"JNJ","form_type":"8-K","filed_at":"2023-08-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"JNJ updates 2023 guidance post-Kenvue separation; raises sales & EPS outlook, cuts share count","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Updated 2023 guidance: Reported Sales Growth 7.0%-8.0%, Adjusted EPS $10.00-$10.10 (12.5% growth at midpoint).","Reduced share count by ~191M shares; partial-year benefit of ~73.5M shares adds $0.28 to EPS.","Received $13.2B cash from Kenvue debt offering and IPO; retains 9.5% equity stake in Kenvue.","Consumer Health now reported as discontinued ops; expects ~$20B gain in Q3 2023.","Maintains quarterly dividend of $1.19/share; H1 2023 continuing ops sales $42.4B (+5.9% total)."],"consensus_eps_estimate":null,"consensus_eps_actual":1.93,"consensus_revenue_estimate":null,"consensus_revenue_actual":50276000000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":556765211700.5051,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":286227,"accession_number":"0000200406-23-000086","cik":200406,"company_name":"JOHNSON & JOHNSON","ticker":"JNJ","form_type":"8-K","filed_at":"2023-08-25T23:59:59+00:00","items":["2.01","9.01"],"status":"ready","headline":"Johnson & Johnson completes split-off exchange of 1.53B Kenvue shares for 190.96M JNJ shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Completed split-off exchange offer on Aug 23, 2023: exchanged 1,533,830,450 Kenvue shares for 190,955,435 JNJ shares.","Transaction effectively separates Kenvue (consumer health) from JNJ, reducing JNJ share count by ~190.96M shares.","Kenvue common stock now held by former JNJ shareholders who tendered shares in the exchange offer."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":556765211700.5051,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":286226,"accession_number":"0001628280-23-026095","cik":200406,"company_name":"JOHNSON & JOHNSON","ticker":"JNJ","form_type":"8-K","filed_at":"2023-07-28T23:59:59+00:00","items":["5.04","9.01"],"status":"ready","headline":"JNJ notifies directors/officers of potential blackout period Aug 15-28 amid Kenvue share exchange offer","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Blackout triggered if 50%+ of plan participants tender JNJ shares held in Stock Fund as part of Kenvue exchange offer.","Expected blackout period: August 15, 2023 at 4 p.m. ET through the week of August 28, 2023.","During blackout, directors and officers prohibited from trading JNJ shares acquired via service, except via the offer.","Notice provided under Section 306(a) of Sarbanes-Oxley Act and Regulation BTR; advance SEC filing made."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":556765211700.5051,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":286225,"accession_number":"0001628280-23-025388","cik":200406,"company_name":"JOHNSON & JOHNSON","ticker":"JNJ","form_type":"8-K","filed_at":"2023-07-24T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"JNJ Q2 preliminary: sales $25.53B (+6.3%), EPS $1.96 (+8.9%)","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net earnings $5.14B vs $4.81B; diluted EPS $1.96 vs $1.80 YoY.","MedTech sales $7.79B (+12.9%) driven by Abiomed and Electrophysiology growth.","Pharmaceutical sales $13.73B (+3.1%); DARZALEX +22.4%, TREMFYA +18.3%, CARVYKTI $117M.","Consumer Health sales $4.01B (+5.4%); OTC +12.0%, Skin Health/Beauty +2.0%.","Preliminary results subject to adjustment; six-month net earnings fell 49.1% due to $7.2B other expense (Kenvue)."],"consensus_eps_estimate":null,"consensus_eps_actual":1.93,"consensus_revenue_estimate":null,"consensus_revenue_actual":50276000000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":556765211700.5051,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":286224,"accession_number":"0000200406-23-000073","cik":200406,"company_name":"JOHNSON & JOHNSON","ticker":"JNJ","form_type":"8-K","filed_at":"2023-07-20T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"JNJ Q2 sales up 6.3% to $25.5B; raises FY guidance; Kenvue spin-off via exchange offer","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 2023 sales $25.53B (+6.3%); operational sales growth 7.5% excluding COVID-19 vaccine 8.9%.","GAAP diluted EPS $1.96 (+8.9%); adjusted diluted EPS $2.80 (+8.1%).","FY 2023 adjusted operational sales ex-COVID vaccine and adjusted operational EPS guidance midpoints raised.","Board authorizes Kenvue share split-off via exchange offer as next step in separation."],"consensus_eps_estimate":null,"consensus_eps_actual":1.93,"consensus_revenue_estimate":null,"consensus_revenue_actual":50276000000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":556765211700.5051,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":306030,"accession_number":"0001193125-23-138287","cik":200406,"company_name":"JOHNSON & JOHNSON","ticker":"JNJ","form_type":"8-K","filed_at":"2023-05-08T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"J&J completes Kenvue IPO at $22/share, retains 89.6% stake; net proceeds $4.24B","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Kenvue IPO priced at $22.00 per share; 198.7M shares sold including over-allotment.","Net proceeds of $4,241M paid to J&J as partial consideration for transferred consumer health business.","J&J owns 1,716,160,000 Kenvue shares (89.6%) post-IPO; will continue to consolidate Kenvue.","Separation Agreement and ancillary agreements (tax, employee, IP, trademark) executed May 3, 2023.","J&J may pursue a full distribution or other disposition of remaining Kenvue shares later."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":556765211700.5051,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":306029,"accession_number":"0000200406-23-000059","cik":200406,"company_name":"JOHNSON & JOHNSON","ticker":"JNJ","form_type":"8-K","filed_at":"2023-05-01T23:59:59+00:00","items":["5.02","5.07"],"status":"ready","headline":"Thibaut Mongon leaving JNJ executive roles after Kenvue IPO; annual meeting results announced","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Thibaut Mongon to step down as EVP, WW Chairman Consumer Health and Executive Committee member upon Kenvue IPO closing; remains Kenvue CEO.","All 12 Johnson & Johnson director nominees elected at annual meeting; each received >1.68B votes in favor.","Shareholders approved advisory say-on-pay (1.685B for, 123M against) and set frequency at 1 year until 2029.","Ratification of PwC as independent auditor for FY2023 passed with 2.049B votes for, 119M against.","Two shareholder proposals—Vaccine Pricing Report and Extended Patent Exclusivities Report—were rejected by wide margins."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":556765211700.5051,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":306028,"accession_number":"0000200406-23-000043","cik":200406,"company_name":"JOHNSON & JOHNSON","ticker":"JNJ","form_type":"8-K","filed_at":"2023-04-18T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"J&J Q1 revenue $24.7B (+5.6%), adj EPS $2.68 (+0.4%); raises FY guidance, increases dividend 5.3%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP net loss $68M ($0.03 loss per share) due to $7.2B one-time charge; adjusted net earnings $7,068M, adj EPS $2.68.","Revenue increased 5.6% to $24.7B; operational growth 9.0%; all segments grew: Consumer +7.4%, Pharma +4.2%, MedTech +7.3%.","Company raising 2023 full-year guidance midpoints for adjusted operational sales and adjusted operational EPS.","Board declared 5.3% dividend increase to $1.19/share ($4.76 annual); 61st consecutive year; payable June 6, record May 23."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.03,"consensus_revenue_estimate":null,"consensus_revenue_actual":24746000000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":556765211700.5051,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":306027,"accession_number":"0000200406-23-000037","cik":200406,"company_name":"JOHNSON & JOHNSON","ticker":"JNJ","form_type":"8-K","filed_at":"2023-04-04T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"J&J subsidiary LTL re-files Chapter 11; J&J commits $8.9B to resolve talc claims","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["LTL re-filed for Chapter 11 bankruptcy to resolve all cosmetic talc claims against J&J in North America.","J&J agreed to contribute up to $8.9 billion present value ($12 billion nominal) over 25 years.","J&J records a Q1 2023 charge of $6.9 billion, above the $2 billion committed in the October 2021 filing.","Over 60,000 current claimants support the reorganization plan, which does not involve J&J itself filing for bankruptcy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":556765211700.5051,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":306026,"accession_number":"0000200406-23-000032","cik":200406,"company_name":"JOHNSON & JOHNSON","ticker":"JNJ","form_type":"8-K","filed_at":"2023-04-03T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Director Ian E. L. Davis retires from Johnson & Johnson board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Ian E. L. Davis retired as a director effective March 31, 2023, per board refreshment criteria.","Retirement is personal, not due to any disagreement with management on operations, policies, or practices.","Mr. Davis had previously disclosed he would not stand for re-election at the 2023 annual meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":556765211700.5051,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":325239,"accession_number":"0000200406-23-000011","cik":200406,"company_name":"JOHNSON & JOHNSON","ticker":"JNJ","form_type":"8-K/A","filed_at":"2023-02-15T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Johnson & Johnson appoints Paula A. Johnson to Board of Directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Paula A. Johnson, MD, MPH, President of Wellesley College, appointed effective February 14, 2023.","She will serve on the Nominating & Corporate Governance Committee effective April 27, 2023.","Compensation as a non-employee director follows the 2023 Proxy Statement terms.","CEO Joaquin Duato highlighted her expertise in medical research, public health, and health policy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":556765211700.5051,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":325241,"accession_number":"0000200406-23-000008","cik":200406,"company_name":"JOHNSON & JOHNSON","ticker":"JNJ","form_type":"8-K","filed_at":"2023-02-14T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Johnson & Johnson appoints Paula A. Johnson, President of Wellesley, to Board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Paula A. Johnson, MD, MPH, President of Wellesley College, appointed to Board effective Feb 14, 2023.","Will serve on Nominating & Corporate Governance Committee effective April 27, 2023.","CEO Joaquin Duato cites her expertise in medical research, public health, and health policy.","Ms. Johnson will receive standard non-employee director compensation per 2023 Proxy Statement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":556765211700.5051,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":325240,"accession_number":"0000200406-23-000005","cik":200406,"company_name":"JOHNSON & JOHNSON","ticker":"JNJ","form_type":"8-K","filed_at":"2023-01-24T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"J&J Q4 sales fall 4.4% to $23.7B; adjusted EPS rises 10.3% to $2.35; 2023 guidance issued","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 reported sales $23.7B, -4.4% YoY; operational growth ex-COVID vaccine +4.6%.","Q4 GAAP EPS $1.33 (down 24.9%); adjusted EPS $2.35 (+10.3%).","Full-year 2022 sales $94.9B (+1.3% reported); operational growth 6.1%.","FY2022 GAAP EPS $6.73 (-13.8%); adjusted EPS $10.15 (+3.6%).","2023 guidance: adj. operational sales growth ex-COVID vaccine +4.0%; adj. EPS ~$10.50 (+3.5%)."],"consensus_eps_estimate":null,"consensus_eps_actual":6.73,"consensus_revenue_estimate":null,"consensus_revenue_actual":94943000000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":556765211700.5051,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":342999,"accession_number":"0001193125-22-311072","cik":200406,"company_name":"JOHNSON & JOHNSON","ticker":"JNJ","form_type":"8-K","filed_at":"2022-12-22T23:59:59+00:00","items":["1.01","2.01","7.01","9.01"],"status":"ready","headline":"JNJ completes $16.6B acquisition of Abiomed; $380/sh + CVR up to $35/sh","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Tender offer expired with ~57.1% of shares tendered; all conditions satisfied.","Abiomed will operate as a standalone business within JNJ's MedTech segment.","Transaction expected slightly dilutive to neutral to adjusted EPS in year one, accretive by $0.05 in 2024.","Abiomed common stock ceased trading on NASDAQ upon completion."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":556765211700.5051,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2022-12-22T23:59:59+00:00|342999"}